For state-licensed 503A compounding pharmacies and FDA-registered 503B outsourcing facilities. We build the underwriting file and place it with acquiring banks — we are not the bank and do not make the decision.
Not for research-use-only peptide sellers, consumer research-peptide websites or research-chemical storefronts. That is a policy rather than a preference, and it is the reason a pharmacy file from us reads differently to an acquirer.
This is the whole eligibility test. It is short on purpose.
Read the Peptide Platform Terms for the full eligibility and prohibited-conduct language.
These are the items our resolver actually requires, not a generic list. They differ between 503A and 503B because the businesses differ — a 503A dispenses against a prescription, a 503B produces without one.
Current, in good standing, for the entity taking payment.
Checked against the issuing board.
The licensed pharmacist supervising compounding.
Licensing evidence for that pharmacist.
503A depends on compounding for an identified patient against a valid prescription.
What is compounded and dispensed. Merchant eligibility is not product eligibility.
Where bulk drug substances and active ingredients come from.
For the substances you compound with.
The operating entity, the site, the descriptor and the licenses must correspond.
Board action, inspection findings or enforcement correspondence, if any.
Checkable against the FDA registered-facility list.
Current registration for the specific facility being submitted.
Registration alone does not establish cGMP compliance — FDA says so explicitly.
Inspections, Form FDA 483 observations, warning letters, recalls.
How product and adverse-event obligations are met.
Alongside the federal registration.
What the facility produces.
Bulk drug substances, used only where permitted.
The facility submitted must be the facility operating.
Disclosed rather than discovered.
Being a 503A pharmacy or a registered 503B facility does not make every product eligible for processing.
AltirasPay does not determine whether a particular peptide may lawfully be compounded, whether a bulk drug substance satisfies applicable requirements, or whether a preparation qualifies for an exemption. Each merchant remains responsible for that, and we may decline to submit a product, URL or business model that presents regulatory or card-network concerns. Saying this plainly up front is cheaper than discovering it after boarding.
Yes. Approval depends on state licensing being current, the prescription model, what is compounded, ingredient sourcing and the acquirer's own appetite. AltirasPay prepares the file; the acquiring bank decides.
No. The AltirasPay Peptide Platform is limited to qualifying 503A compounding pharmacies and 503B outsourcing facilities. Research-use-only peptide sellers, consumer research-peptide websites and research-chemical sellers are not eligible, and RUO transactions may not be processed through an account obtained through this platform.
A 503A pharmacy compounds for an identified patient against a valid prescription and is licensed by a state board. A 503B outsourcing facility registers with the FDA facility by facility, produces without patient-specific prescriptions, and carries cGMP and inspection obligations. They are underwritten differently and the document list differs.
No. FDA states explicitly that registration alone does not establish cGMP compliance or overall statutory compliance, and no acquirer treats it that way. It is one item in the file.
No. The entity presented must correspond to the operating entity, and a marketing company, shell entity or research company may not be substituted for the actual merchant. Misdescribing the business is the most common reason an approved account is later closed.
No. Merchant eligibility is not product eligibility. Acceptance of an application does not mean every compounded drug, bulk substance or formulation is eligible for processing, and AltirasPay does not determine whether a particular peptide may lawfully be compounded.
The file is usually built within 24 to 48 hours of having the documents. The bank's own decision typically takes 7 to 10 days, and that clock is theirs rather than ours.
No. AltirasPay is a merchant sales, technology and application-support organization. It does not approve accounts, set final pricing, determine reserves or hold funds — those are the Provider's decisions.
Tell us which you are and we resolve the document list against your actual operation rather than sending you everything. If you are already processing, a statement tells us more in five minutes than a call does in an hour.
Applying commits you to nothing and is not an approval. The acquiring bank decides placement, pricing, reserves and terms. AltirasPay is not a pharmacy, a healthcare provider, a regulator or a law firm, and does not determine whether any product is lawful or FDA compliant.
